Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human progressive-ratio performance: maintenance by pentobarbital.

D R McLeod, R R Griffiths

    Psychopharmacology
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Psychedelic-assisted psychotherapy to treat psychiatric and existential distress in life-threatening medical illnesses and palliative care.

    Neuropharmacology·2022
    Same author

    Dental abnormalities in Schimke immuno-osseous dysplasia.

    Journal of dental research·2012
    Same author

    Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

    Psychopharmacology·2006
    Same author

    Normal physiological emotions but differences in expression of conscious feelings in children with high-functioning autism.

    Journal of autism and developmental disorders·2006
    Same author

    An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers.

    Behavioural pharmacology·2005
    Same author

    Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition.

    Journal of medical genetics·2005
    Same journal

    Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.

    Psychopharmacology·2026
    Same journal

    Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CB<sub>1</sub> and 5-HT<sub>1A</sub> receptor signaling.

    Psychopharmacology·2026
    Same journal

    Fentanyl decreases arterial blood oxygen saturation more than furanylfentanyl in mice due to increased apnea.

    Psychopharmacology·2026
    Same journal

    Suicide attempt risk among patients receiving methylphenidate: a retrospective cohort study.

    Psychopharmacology·2026
    Same journal

    Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

    Psychopharmacology·2026
    Same journal

    OPRD1 rs4654327 and Outcomes of Extended-Release Naltrexone in Alcohol Use Disorder: An Exploratory Prospective Pharmacogenetic Study.

    Psychopharmacology·2026
    See all related articles

    This study found that pentobarbital increased drug liking and effects in individuals with a history of sedative abuse. Progressive-ratio schedules effectively measured the reinforcing properties of pentobarbital.

    Area of Science:

    • Pharmacology
    • Behavioral Neuroscience
    • Addiction Research

    Background:

    • Sedative drug abuse poses significant public health challenges.
    • Understanding the reinforcing properties of sedative drugs is crucial for developing effective treatments.
    • Previous research has explored various methods to assess drug reinforcement.

    Purpose of the Study:

    • To evaluate the reinforcing efficacy of pentobarbital using progressive-ratio schedules.
    • To assess the dose-response relationship of pentobarbital on drug self-administration.
    • To investigate subjective and objective measures of pentobarbital's effects.

    Main Methods:

    • Five human volunteers with histories of sedative drug abuse participated.
    • Pentobarbital (200, 400, 600 mg) or placebo was self-administered under double-blind, letter-coded conditions.

    Related Experiment Videos

  • A progressive-ratio schedule required participants to complete tasks (button pressing or cycling) with increasing demands to earn a dose.

    • Main Results:

    • Pentobarbital produced dose-related increases in the maximum progressive-ratio requirement completed.
    • Subject and staff ratings of drug effect, as well as subjective drug liking, were dose-dependently increased.
    • Scores on the PCAG scale of the Addiction Research Center Inventory also showed dose-related increases.

    Conclusions:

    • Progressive-ratio schedules are sensitive and valid for assessing the relative reinforcing efficacy of drugs.
    • Pentobarbital demonstrates significant reinforcing properties in individuals with a history of sedative abuse.
    • This methodology can inform the development of interventions for sedative drug abuse.